Kura Oncology, Inc. (KURA) financial statements (2021 and earlier)

Company profile

Business Address 12730 HIGH BLUFF DRIVE, SUITE 400
SAN DIEGO, CA 92130
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments6332371799368860
Cash and cash equivalents32526161110150
Short-term investments308211163825870 
Receivables 00000 
Other undisclosed current assets432111 
Total current assets:6372401819569870
Noncurrent Assets
Operating lease, right-of-use asset6 
Property, plant and equipment20(0)000 
Restricted cash and investments0      
Other noncurrent assets121110 
Other undisclosed noncurrent assets  0  0 
Total noncurrent assets:1021110 
TOTAL ASSETS:6472421829670870
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:2315138540
Accounts payable3441110
Accrued liabilities21112 0
Employee-related liabilities743221 
Interest and dividends payable      0
Other undisclosed accounts payable and accrued liabilities12764 2 
Debt30 2   
Derivative instruments and hedges, liabilities     0 
Due to related parties      0
Other undisclosed current liabilities  0011 
Total current liabilities:26161410550
Noncurrent Liabilities
Long-term debt and lease obligation107867  
Long-term debt, excluding current maturities47867  
Operating lease, liability6 
Liabilities, other than long-term debt000000 
Other liabilities000000 
Total noncurrent liabilities:1088670 
Other undisclosed liabilities      (0)
Total liabilities:362321161350
Stockholders' equity
Stockholders' equity attributable to parent, including:611219161805782(0)
Common stock0000000
Additional paid in capital9134313111691111080
Accumulated other comprehensive income (loss)00(0)(0)(0)(0) 
Accumulated deficit(303)(213)(150)(89)(54)(26) 
Other undisclosed stockholders' equity attributable to parent      (0)
Total stockholders' equity:611219161805782(0)
TOTAL LIABILITIES AND EQUITY:6472421829670870

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Operating expenses(92)(67)(63)(36)(28)(24)(0)
Operating loss:(92)(67)(63)(36)(28)(24)(0)
Nonoperating income242111 
Investment income, nonoperating   100 
Interest and debt expense(1)(1)(0)(1) (0)(0)
Net loss:(90)(64)(61)(36)(28)(23)(0)
Other undisclosed net income attributable to parent1101 0 
Net loss available to common stockholders, diluted:(90)(63)(60)(35)(28)(23)(0)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(90)(64)(61)(36)(28)(23)(0)
Other comprehensive income (loss)(0)0(0)    
Comprehensive loss:(90)(63)(61)(36)(28)(23)(0)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent11010(0) 
Comprehensive loss, net of tax, attributable to parent:(90)(63)(61)(35)(27)(23)(0)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: